Health Professional Radio - Podcast

Carisma Therapeutics, Inc. announced (March 2021) that the first patient has been dosed in the Phase 1 multi-center clinical trial for CT-0508, studying the potential of chimeric antigen receptor macrophages (CAR-Ms) for cancer immunotherapy, specifically in solid tumors.  Dr. Debora Barton, MD, Chief Medical Officer at Carisma is here to talk about this novel approach in gene-based therapy development, as it is the first time CAR--engineered macrophages are being studied in humans. CAR-T cell therapy has revolutionized how cancer is treated and revealed the power of gene-based therapies, and it has met challenges with solid tumors. Carisma’s novel approach to immunotherapy may uncover potential treatment options that aim to address the unmet needs of patients, who are battling hard-to-treat cancers. Debora Barton joined Carisma Therapeutics in November 2019. She brings 18 years of oncology experience, both in academia as a practicing physician and in the biotechnology/pharmaceutical industry. In her rol